"The science shows that there is greater benefit from pulmonary rehab than any pharmacology we can give a COPD patient, so a ...

Canadian wildfire smoke has entered the Upper Midwest and poses significant health impacts in the hardest-hit areas.

Yet thanks to a new hospital-based educational and advocacy initiative for COPD patients, Croswell has been managing well at ...

People with COPD are vulnerable to small increases in PM2.5, with each 1 μg/m3 rise in long-term exposure linked to a 3.8% ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...